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A B S T R A C T
Nanotechnology, the manipulation of matter on atomic and molecular scales, is a relatively new
branch of science. It has already made a significant impact on clinical medicine, especially in
oncology. Nanomaterial has several characteristics that are ideal for oncology applications,
including preferential accumulation in tumors, low distribution in normal tissues, biodistribution,
pharmacokinetics, and clearance, that differ from those of small molecules. Because these
properties are also well suited for applications in radiation oncology, nanomaterials have been used
in many different areas of radiation oncology for imaging and treatment planning, as well as for
radiosensitization to improve the therapeutic ratio. In this article, we review the unique properties
of nanomaterials that are favorable for oncology applications and examine the various applications
of nanotechnology in radiation oncology. We also discuss the future directions of nanotechnology
within the context of radiation oncology.
J Clin Oncol 32:2879-2885. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Nanotechnology, the manipulation of matter on
atomic and molecular scales, is a relatively new
branch of science. The idea was first discussed by
world-renowned physicist and Nobel laureate Rich-
ard Feynman in 1959.1 In a lecture titled “There’s
Plenty of Room at the Bottom,” he discussed the
possibility of engineering materials on a nanometer
scale and the potential applications of such technol-
ogy. Although impossible at the time, advances in
physics, chemistry, and materials science eventually
made nanomaterials possible in the 1970s.2 The
term “nanotechnology,” however, did not become
popularized until the 1980s.3 Despite being only
four decades old, nanotechnology has made rapid
progress and is evident in a wide range of applica-
tions, from industrial manufacturing to consumer
cosmetics.4 Today, it is estimated that there are
more than 1,600 nanotechnology-based con-
sumer products, with new ones entering the mar-
ket at a rapid pace.5
One of the key applications of nanotechnology
is in medicine, especially for the treatment of can-
cer.6,7 Engineering matter on a nanoscale can give
nanoparticles (NPs; nanomaterials that are  100
nm in size) unique properties that small molecules
and bulk materials do not possess. These properties
have been used for the development of novel
medical diagnostics and therapeutics. For exam-
ple, iron oxide NPs possess superparamagnetic
properties that are not present in other iron oxide
materials.8 In the presence of an external mag-
netic field, iron oxide NPs can provide strong
paramagnetic signals at low doses, which make
them excellent contrast agents in magnetic reso-
nance imaging (MRI).
Nanomaterials also have several characteristics
that are ideally suited for oncology applications.
These include the enhanced permeability and reten-
tion (EPR) effect, distinct biodistribution and phar-
macokinetics, and controlled release.9,10 The leaky
vasculature and inefficient lymphatics of tumors al-
low NPs to extravasate into tumors but prevent their
exit back into circulation.11,12 This results in the
preferential accumulation of NPs in tumors, which
is called the EPR effect.11,13 Such preferential accu-
mulation is advantageous for both diagnostic and
therapeutic applications. NPs also have a unique
biodistribution when compared with small mole-
cules. Because of their large size compared with
small molecules, NPs are unable to penetrate nor-
mal vasculature and capillaries. This leads to lower
accumulation in organs such as skin, lung, and heart
when compared with small molecules.12 Moreover,
unlike small molecules that are cleared via several
different routes of excretion from the body, NPs are
mainly removed from the circulation through the
mononuclear phagocytic system and hepatic excre-
tion.14 This clearance pattern provides NPs with dif-
ferent pharmacokinetic properties than small
molecules and makes NPs well suited for the delivery
of chemotherapeutics. Finally, many NPs can be
engineered to release their content in a slow and
controlled fashion. This controlled release can be
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beneficial for therapeutic applications because it increases the expo-
sure of tumor cells to the therapeutic cargo in NPs.
Although much of the research and translation efforts on nano-
technology in oncology have been focused on the development of
diagnostics and chemotherapy delivery,15 there has been strong inter-
est in applying nanotechnology to improve radiation oncology. This
review discusses the impact that nanotechnology has had on radiation
oncology and will have on potential future applications.
NP PLATFORMS
NPs have been engineered from a wide range of materials that can be
divided into inorganic and organic NPs.6,16 Inorganic NPs include
carbon-based NPs, quantum dots, and metal NPs. The ability to
combine materials with different chemical and physical properties in
inorganic NPs has generated materials with novel properties. One
example is iron oxide NPs, already mentioned. Another is quantum
dots (made of semiconductor materials) that are small enough to
display quantum mechanical properties.17 In medical applications,
quantum dots can be engineered to have specific fluorescent emission
properties with minimal photobleaching. Because of these unique
properties, inorganic NPs have generally been used for diagnostics.
Organic NPs are usually formulated with biocompatible materi-
als such as lipids, biocompatible polymers, nucleic acids, and peptides.
Well-established organic NP platforms include liposomes and other
lipid-based micelles, polymeric micelles, dendrimers, and DNA NPs.
Because of their biocompatibility, organic nanoplatforms have pri-
marily been used for therapeutic applications. Liposomes are com-
posed of a lipid bilayer, and lipid-based NPs are excellent carriers for
hydrophilic molecules such as water-solution chemotherapeutics and
nucleic acids. Polymeric micelles are generally composed of a hydro-
philic surface and a hydrophobic core.18 The hydrophobic core allows
the delivery of hydrophobic chemotherapeutics such as paclitaxel.
Dendrimers (repetitively branched molecules) and DNA NPs can be
covalently modified with therapeutic agents.
NANOTECHNOLOGY IN IMAGING AND DIAGNOSTICS
Nanotechnology has made a strong impact on medical imaging and
diagnostics. In imaging, advances in nanotechnology have resulted in
the clinical translation of iron oxide NPs as MRI contrast agents. The
most extensively studied agent is the lymphotrophic superparamag-
netic iron oxide NP ferumoxtran-10, which can be used to detect
subcentimeter lymph node metastases.19 The seminal study on feru-
moxtran was conducted in prostate cancer by Harisinghani et al20 on
the detection of clinically occult lymph node metastases. Eighty-eight
patients with resectable prostate cancer underwent MRI imaging with
and without lymphotrophic superparamagnetic NPs followed by
lymph node resection or biopsy. The imaging findings were compared
with and correlated with histopathologic findings. The investigators
found that MRI scans with lymphotrophic superparamagnetic NPs
had significantly higher sensitivity than conventional MRI scans
(90.5% v 35.4%) and had high specificity because they correctly pre-
dicted all patients with lymph node metastases.
In radiation oncology, lymphotrophic superparamagnetic NPs
have been applied to lymph node mapping. Radiation therapy to
regional lymphatics is an important component in the curative treat-
ment of many cancers, including head and neck, breast, and anal
cancers.21-23 Therefore, the delineation (mapping) of at-risk lymph
nodes can be critical in planning radiation treatment.22,24 Lymph
node mapping techniques generally rely on computed tomography
(CT) imaging scans and anatomic surrogates for lymphatics, such as
bony landmarks. The locations of lymph nodes at risk are generally
not well defined, and there is large variation among radiation oncol-
ogists in identifying lymph node treatment volumes. Because lympho-
trophic superparamagnetic NPs can accurately identify lymph nodes
on MRI scans, several studies have used the technique in radiation
lymph node mapping. Shih et al25 studied 18 lymph node–positive
patients with prostate cancer who were part of a larger clinical trial that
evaluated lymphotrophic nanoparticle–enhanced MRI (LN-MRI) in
prostate cancer. The suspected nodal disease on MRI imaging was
biopsied by using CT guidance and was confirmed pathologically. In
total, there were 69 positive nodes, and these nodes were mapped to a
common template on the basis of their relation to skeletal or vascular
anatomy. The investigators found that nodal metastases are largely
localized near vasculature rather than bony anatomy. By using these
pathologically positive nodes, they created a general guide on how to
define lymph node treatment volume for prostate cancer radiotherapy
(Fig 1). In a similar study, MacDonald et al examined LN-MRI in
breast cancer radiation planning. The investigators found that con-
ventional radiotherapy fields do not always adequately cover the
lymph nodes at risk, with the 50-Gy isodose line encompassing only
60% of nodes identified by LN-MRI. On the basis of these data, they
recommended a margin when defining lymph node treatment vol-
umes by using CT imaging. Further clinical translation of iron oxide
NPs in radiation oncology has been hindered by the lack of clinical
adoption of these agents as MRI contrast agents.
Nanotechnology has also been applied in x-ray generation. Car-
bon nanotubes (CNTs) have been used as electron emitters in x-ray
imaging.26 Unlike conventional x-ray imaging in which this is a single
electron emitter, the CNT x-ray imager uses an array of CNTs with
each CNT functioning as an electron emitter. The advantages of CNT-
based x-ray imaging over conventional imaging include higher reso-
lution, lower radiation dose, and smaller sized equipment. These
approaches have been developed for breast tomosynthesis diagnostic
BA
Fig 1. Metastatic nodes referenced to pelvic vessels with a 2-cm clinical target
volume expansion to the region along pelvic vessels at greatest risk. (A)
Anterior-posterior view. (B) Left lateral view. Image adapted.1
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studies, and the machines are in clinical trial. Because of these charac-
teristics, CNT has been applied in microradiotherapy systems for
preclinical research.27 Because of its ability to generate x-ray beams on
the micrometer scale, CNT has also been used in the development of a
microbeam radiation therapy system.28 Such machines may be useful
in understanding the biologic effects of radiotherapy at the single-
cell level.
Nanotechnology-based medical diagnostics have been translated
clinically, with several assays already in clinical use.29,30 The enthusi-
asm for nano-diagnostics is a result of their ability to detect analytes at
femtomolar (1015 M) concentrations, several hundred times more
sensitive than conventional diagnostics. Some of these diagnostics can
be directly applied in radiation oncology. For example, Thaxton et al31
developed a novel bio-barcode assay to detect prostate-specific anti-
gen (PSA) by using gold NPs (Fig 2). This assay was evaluated in a pilot
study with 18 men who had undergone radical prostatectomy and
were deemed to have undetectable PSA by conventional PSA tests. The
new barcode assay was able to detect PSA as low as 330 fg/mL. Despite
the initially undetectable levels ( 0.1 mg/mL) of PSA in these men,
the investigators found that men who had rapidly rising PSA detected
by using the barcode assay had worse clinical outcomes. They sug-
gested that such ultrasensitive PSA tests may be helpful in better
identifying men who need salvage radiotherapy after surgery.
Other NP-based diagnostics hold potential in improving early
detection of cancer and monitoring disease progression as well as
disease recurrence.32 Shao et al33 reported on a novel device that is
capable of detecting circulating microvesicles that are secreted by
glioblastoma tumor cells. By using the detected microvesicles, the
investigators were able to monitor and predict treatment response to
two chemotherapeutics in a mouse model. Nanotechnology has also
been incorporated into devices to capture circulating tumor cells
(CTCs).34 CTC devices also allow early detection of cancer and real-
time monitoring of disease. The significance of CTCs is being explored
for use in radiation oncology.35 Collectively, these NP-based diagnos-
tic assays can provide real-time information on radiotherapy treat-
ment response. They may also increase the curative management of
cancers that involve radiotherapy.
INORGANIC NPS AS RADIOSENSITIZERS
There has been long-standing interest in the development of radiosen-
sitizers, agents that can sensitize tumor cells to radiotherapy, to im-
prove the therapeutic ratio of radiotherapy.36 Current efforts have
generally focused on chemotherapeutics and targeted agents. One
unique strategy is to increase the radiation dose within tumor tissue by
using material with high atomic numbers (Z). This is because the dose
absorbed by any tissue is related to the Z2 of the material.37 If an agent
can increase the overall effective Z of tumor without affecting the Z of
nearby tissue, it can lead to increased radiotherapy dose to tumors and
higher therapeutic efficacy.
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Fig 2. Schematic of the gold (Au) nanopar-
ticle (NP) barcode assay. (A) Barcode DNA-
functionalized Au-NPs (30 nm) are conjugated
to PSA-specific antibodies through barcode
terminal tosyl (Ts) modification to generate
the co-loaded PSA Au-NP probes. In a second
step, the PSA Au-NP probes are passivated
with BSA. (B) The bio-barcode assay is
a sandwich immunoassay. First, MMPs
surface-functionalized with monoclonal anti-
bodies to PSA are mixed with the PSA target
protein. Next, PSA Au-NP probes are added to
sandwich the MMP-bound PSA. PSA-specific
DNA barcodes are then released into solution
and detected using the scanometric assay,
which takes advantage of Au-NP catalyzed
silver enhancement. Approximately half of the
barcode DNA sequence (green) is comple-
mentary to the “universal“ scanometric Au-NP
probe DNA, and the other half (purple) is
complementary to a chip-surface immobilized
DNA sequence that is responsible for sorting
and binding barcodes complementary to the
PSA barcode sequence. Ag, silver, BSA, bo-
vine serum albumin; MMP, magnetic mi-
croparticle probe; PSA, prostate-specific
antigen; SH, sulfur and hydrogen; Ts, tosyl
(blue symbol) PSA-specific antibodies. Im-
age adapted.28
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By using this strategy, Maggiorella et al38 studied hafnium oxide
NPs as radiosensitizers. The investigators engineered hafnium oxide
NPs (NBTXR3) that are approximately 50 nm in size. NBTXR3 was
evaluated by using tumor xenograft models with two sarcoma cell
lines and a colorectal cancer cell line. The agent was given through
intratumoral injection. The investigators found that NBTXR3 dem-
onstrated radiosensitizing effects on tumor cells, and the addition of
NBTXR3 led to increased delay in tumor growth. They did not observe
significant toxicity in mice. NBTXR3 is currently being evaluated
clinically as a radiosensitizer in two phase I trials: one in soft tissue
sarcoma of the extremity (NCT01433068) and the other in locally
advanced squamous cell carcinoma of the oral cavity or orophar-
ynx (NCT01946867).
Many groups have also studied gold NPs as radiosensitizers.39
Like hafnium, gold is a high Z material and an excellent absorber of
x-rays. Gold has a good safety profile because it is inert (elemental
gold) and it has been used in medical therapies.40 Several studies have
demonstrated the radiosensitization effects of gold NPs in vitro and in
vivo.41-43 However, these agents have not been evaluated clinically.
The main barrier to clinical translation for high Z inorganic NPs is the
lack of a clearance pathway for these NPs.14,44 Without clearance, it is
impractical to administer these agents intravenously as radiosensitiz-
ers. Thus, the main route of administration is intratumoral injection,
which has limited utility in clinical radiation oncology at present.
NANOTHERAPEUTICS TO IMPROVE CHEMORADIOTHERAPY
Chemoradiotherapy, the concurrent administration of chemotherapy
and radiotherapy, has been an important treatment paradigm in on-
cology.45 Although it has improved survival and disease control, che-
moradiotherapy also has increased toxicity when compared with
sequential treatment or either treatment alone.45 Therefore, there has
been strong interest in improving the therapeutic ratio of chemora-
diotherapy. One approach is to improve the delivery of chemotherapy
to the tumors while reducing drug dose to normal tissue (Fig 3).
However, previous efforts using traditional drug delivery techniques
have been unsuccessful.46
As mentioned previously, NPs possess several important char-
acteristics that are well-suited for the delivery of chemotherapeu-
tics in chemoradiotherapy, including preferential accumulation in
tumors, inability of NPs to penetrate normal vasculature leading to
lower drug dose to normal tissues and reduced toxicity,12 and slow
and controlled drug delivery. Therefore, NP delivery of chemother-
apeutics has the potential to significantly improve the therapeutic
ratio of chemoradiotherapy.10
Liposomal formulations of doxorubicin were the first NP thera-
peutics that were developed for the clinical treatment of cancer.9
Clinically, liposomal doxorubicin has been evaluated in several early-
phase clinical trials of chemoradiotherapy.10 Koukourakis et al47 con-
ducted most of these studies. His group first reported a phase I trial on
the use of liposomal doxorubicin (Caelyx) with conventionally frac-
tionated radiotherapy for locally advanced non–small-cell lung cancer
(NSCLC) and head and neck cancer. As expected, they found the
dose-limiting toxicities were mucositis for treatment of head and neck
cancer and esophagitis for treatment of NSCLC. In a follow-up phase
I/II study, patients with inoperable (stage IIIb; T3,4-N2,3-M0)
NSCLC were enrolled to receive docetaxel, doxorubicin, and radio-
therapy.48 Grade 3 and higher esophagitis, which was the dose-
limiting toxicity, developed in nine (36%) of 25 patients. The response
rates were 40% complete response (CR) and 47% partial response.
Liposomal formulations of doxorubicin have also been investigated in
chemoradiotherapy for cervical cancer, recurrent breast cancer, and
bladder cancer. Despite promising results from these small clinical
trials, liposomal doxorubicin was not adopted into chemoradio-
therapy treatment regimens. The main reason is that small mole-
cule doxorubicin has not been used in chemoradiotherapy.
Moreover, although the clinical results from the liposomal doxo-
rubicin were promising, they were not clearly superior to standard
chemoradiotherapy regimens.
Liposomal formulations of cisplatin, although not as extensively
studied as doxorubicin, have also been investigated in early-phase
clinical trials. In 20 patients with head and neck cancer treated at the
University of Pennsylvania, Rosenthal et al49 examined liposomal
cisplatin as a radiosensitizer concurrent with conventionally fraction-
ated radiotherapy. Grade 3 skin and mucosal toxicities within the
radiation field were minimal, occurring in only one and six patients,
respectively. Furthermore, 11 (55%) of the 20 patients had an initial
CR at the primary tumor site after completing treatment. In a study of
12 patients with locally advanced gastric cancer who received lipo-
somal cisplatin, fluorouracil, and concurrent radiation therapy, high
CR rates and minor toxicities were also observed.50 CR rates improved
from 33% in patients treated with four cycles to 80% in patients
treated with five cycles of combined chemoradiotherapy with lipo-
somal cisplatin. The toxicity profile was comparable with that of
conventional cisplatin. These results on liposomal cisplatin were en-
couraging and await validation in larger clinical trials.
Polymer-drug conjugates can be considered NPs since they are
nanometers in size, although they do not possess some of the key
properties of NPs, such as controlled drug release. Several preclinical
studies have examined polymer-drug conjugates in chemoradiother-
apy, including polymer-gemcitabine and polymer-paclitaxel (PG-
TXL).51-53 Preclinical data from PG-TXL have led to two clinical
studies evaluating it as a radiosensitizer. The first study was a phase I
A B
Fig 3. Small molecule (A) versus nanoparticle therapeutics (B) in chemoradio-
therapy for head and neck squamous cell carcinoma. Axial computed tomography
images of a patient with head and neck squamous cell carcinoma. Areas outlined
in red are tumors that should receive high-dose radiation. (A) Small molecule
chemotherapeutics (depicted by small orange dots) distributes throughout tissue
resulting in large volume of normal tissue receiving radiation and drug. (B) In
contrast, nanoparticle drugs (large orange dots) accumulate in tumors, which
limits drug dose to normal tissue.
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trial using PG-TXL with concurrent radiotherapy in esophageal and
gastric cancer.54 The other trial studied PG-TXL with temozolomide
and radiotherapy in high-grade glioma.55 Unfortunately, combining
temozolomide and PG-TXL led to high rates of and prolonged (5
months) hematologic toxicity.
NP albumin-bound (nab) paclitaxel, the most recently approved
NP chemotherapeutic, has been evaluated preclinically in chemora-
diotherapy.56 Mice bearing ovarian or mammary carcinomas were
treated with nab-paclitaxel, radiotherapy, or both. Nab-paclitaxel im-
proved radiosensitization, lowering the dose to achieve 50% tumor
cure from 54.3 Gy to 35.2 Gy. The greatest treatment effect occurred
when radiation was given 2 to 3 days after nab-paclitaxel was
administered. Currently, several phase III chemoradiotherapy
clinical trials in lung, esophageal, head and neck, endometrial, and
cervical cancer are evaluating the concurrent administration of
nab-paclitaxel with radiotherapy.
Current clinical and preclinical research efforts on nanothera-
peutics have focused on polymeric NP platforms. Several polymeric
NPs have been evaluated clinically, and one polymeric micelle formu-
lation (Genexol-PM) has been approved for clinical use in Korea.9
Although none of these polymeric NPs have been studied clinically in
chemoradiotherapy, there are several preclinical studies. Our group
has evaluated Genexol-PM with external beam radiotherapy in a
mouse model of NSCLC.57 Genexol-PM was compared with pacli-
taxel at equivalent doses of paclitaxel. We found that chemoradiother-
apy with Genexol-PM was more effective than with paclitaxel in vivo
with potentially lower toxicity since there is less paclitaxel dose in the
normal lung with Genexol-PM than paclitaxel at 6 hours after admin-
istration. Jung et al58 also studied polymeric NP formulations of pac-
litaxel and docetaxel with radiotherapy in mouse models of NSCLC.
They observed enhanced synergistic effect with reduced survival frac-
tion of NSCLC cells in vitro and enhanced tumor growth delay in vivo
in xenograft mice.
In addition to established chemotherapeutics, NPs can also de-
liver potent radiosensitizers, such as DNA double-strand repair inhib-
itors, that are too toxic to administer as small molecules. We have
demonstrated proof of principle of this approach by engineering an
NP formulation of wortmannin.59 Wortmannin is a potent radiosen-
sitizer that inhibits DNA repair. However, it has high hematologic and
hepatic toxicity. We demonstrated that NP wortmannin has a signif-
icantly lower toxicity than wortmannin, with the maximum-tolerated
dose of NP wortmannin being three to five times higher than that of
wortmannin. More importantly, NP wortmannin is more effective
than wortmannin as a radiosensitizer and has high therapeutic efficacy
even at low doses. Our results highlight the potential of novel NP
radiosensitizers in chemoradiotherapy. Clinical translation efforts on
polymeric NP therapeutics in chemoradiotherapy are ongoing. We
have recently initiated a phase IB/II trial evaluating CRLX101, an NP
formulation of camptothecin with flurouracil and radiotherapy, in the
neoadjuvanttreatmentof locallyadvancedrectalcancer(NCT02010567).
RADIATION-GUIDED DRUG DELIVERY USING NPS
Radiotherapy can be used to improve the delivery of NP therapeutics
to tumors. Ionizing radiation can increase the vascular permeability of
tumors, further enhancing the EPR effect. This can directly translate
into higher intratumoral nanotherapeutic concentrations after radio-
therapy. Indeed, Lammers et al51 found that radiotherapy can increase
the tumor accumulation of polymer-drug conjugates when examin-
ing polymer-gemcitabine conjugates in chemoradiotherapy in a rat
prostate carcinoma tumor model. This phenomenon was also ob-
served in a separate study by Giustini et al60 using iron oxide NPs.
They found that radiotherapy at 15 Gy significantly increased the
tumor accumulation of iron oxide NPs when they used a syngeneic
mouse breast cancer model. This preferential accumulation effect
can be further enhanced by triggered drug release, such as
hyperthermia-induced drug release, which has been used in con-
junction with radiotherapy.61
In addition to passively improving the distribution of NP thera-
peutics to tumors, radiotherapy can also be used to actively guide NP
drug delivery. Hallahan et al62 identified a peptide that can bind to
integrins on the irradiated tumor microvasculature. By functionaliz-
ing the surfaces of NPs with this unique peptide, the investigators were
able to preferentially deliver liposomes and albumin-based NPs to
tumors. In subsequent preclinical studies, they demonstrated that the
peptide can also be used to target iron platinum NPs,63 nab-paclitaxel,64
and liposomal doxorubicin.65 Each study demonstrated that radiother-
apy enhanced tumor-targeted NP delivery, which resulted in higher
therapeutic efficacy. The data collectively suggest that radiation-
guided drug delivery can be a novel strategy in cancer treatment.
FUTURE DIRECTIONS
Innovation and progress in radiation oncology have traditionally been
driven by advances in technology. For example, a key improvement in
radiation oncology was the development of intensity-modulated radi-
ation therapy, which was made possible by progress in physics and
computer science.66 It is entirely possible that the next major driving
force of progress in radiation oncology will be nanotechnology.
In imaging and diagnostics, NP-based agents can improve radi-
ation treatment planning beyond simply producing guidelines on
how to contour lymph node volumes. Radiotherapy can be planned
with the concurrent administration of an NP-based imaging agent for
accurate identification of the tumor volume as well as lymph node
metastases. Such personalized treatment planning may improve ther-
apeutic efficacy as well as reduce toxicity. NP-based assays can also be
used to monitor radiotherapy treatment response in real time, which
may further improve personalized cancer treatment.
There are strong preclinical data demonstrating the potential of
NP-based therapeutics in improving the therapeutic index of radio-
therapy. However, there is a lack of clinical data examining these
agents in conjunction with radiotherapy. Thus, future efforts should
be focused on conducting clinical trials with selected nanotherapeutics
as they enter clinical evaluation. NPs also offer the opportunity to use
clinically potent radiosensitizers that are too toxic to be used in their
molecular form. More preclinical research is needed to determine how
to engineer NPs that are best suited to deliver these radiosensitizers.
Finally, NPs can facilitate the clinical translation of novel biologic
therapies, such as small interfering RNA.67 Such therapeutics may
provide new therapeutic regimens in radiation oncology as well as in
other areas of medicine.
In less than four decades, nanotechnology has made an
impact on radiation oncology. However, we are still in the early
stages of nanotechnology’s clinical development. Today, there are
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many nanotechnology-based diagnostics and therapeutics under
clinical development. By taking advantage of these novel agents as
well as the new technical capabilities offered by nanotechnology,
we can further improve radiotherapy’s therapeutic efficacy, reduce
its toxicity, and enable more personalized treatment.
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